Tagged with M

Bomi Farma Much has changed at Bomi since we last met in 2007. At that time, you were launching your new facilities, with 72,000 square metres of built area, 14 metres free floor height, 108 docks, and 65,000 pallet capacity – it was a very exciting time. What have been the most…

Chiesi Pharmaceuticals BV The Dutch affiliate of Chiesi was established in 2007 when many changes were occurring in the local industry. The new healthcare system policy went into effect and the market was shifting towards a cost-containment structure. What drove Chiesi’s decision to start-up in the Netherlands? Our respiratory product, Foster, was one…

Bristol-Myers Squibb Brazil Two days ago, the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan against chronic diseases for when the UN next addresses the General Assembly in September. What would be your suggestions? If…

Eurofarma Your position unites two somewhat incongruous titles – Director of Sustainability, and New Business. How did this come to be, and what if any overlap is there between these two areas in Eurofarma? I’ve spent my whole career in marketing, beginning in direct-to-consumer marketing in OTCs. In the 2000s, when…

Boehringer Ingelheim Brazil You came to Boehringer Ingelheim in 2009 – what are some of the most exciting milestones and achievements you have presided over during this time? Looking back on almost three years, my assignment was to open this company and to integrate it more with Brazil. We have a quite enlightened…

Ipsen Farmaceutica BV Within our reports we typically like to highlight the personalities of the industry and the stories behind the executives that we meet. As you are still relatively new to Ipsen, what has been the professional trajectory that has brought you to the head of this local affiliate? I came here…

Merck Sharp & Dohme (MSD) Malaysia Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger last year with Schering-Plough, MSD has been #1 in the ethical category and we carry a heavy responsibility to remain…

NEPROFARM In order to understand the culture behind the business that this association represents, what would you say is the perception of OTC and non-prescriptive drugs in the Netherlands? OTC medicines are the medication of choice in the Netherlands. Most people will have some OTC medicines in his cabinet and indeed,…

Ferring Pharmaceuticals Brazil Yesterday the Ministry of Health released an article stating that chronic diseases now account for 70% of all deaths in Brazil, and welcoming suggestions for the national plan against chronic diseases for when the UN next addresses the General Assembly in September. What would be your suggestions? One of the…

Dompe You recently declared that in a context of new emerging challenges for pharmaceutical companies, those who would survive would not be the strongest ones but the most responsive to change. Indeed, having led Dompé Group through this period of changes, you originated a re-organization of the group. Could you give…

Menarini Pharma Netherlands Menarini is an extremely proud Italian company in its origins, but also very reliant on international markets. In 2009 approximately 63% of the group’s consolidated revenues came from abroad. What is the strategic role that the Netherlands and the Dutch market play for Menarini globally? When we started in 1996,…

Boehringer Ingelheim B.V. While already having worked for Boehringer Ingelheim for quite some time, the end of 2010 marked the completion of your first full year as general manager of this Dutch affiliate. What were some of the highlights of the past year and the main lessons that you look forward to carrying…